Advancing bipolar disorder: Key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Canadian Journal of Psychiatry

Volumn 55, Issue 3, 2010, Pages 136-143

  Parikh, Sagar V ^a,b   LeBlanc, Serge R ^a   Ovanessian, Melina M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Antidepressants; Bipolar depression; Bipolar disorder; Clinical trial; Mania; Mood stabilizers; Psychosocial treatment; Suicidality; Systematic Treatment Enhancement Program for Bipolar Disorder (STEP BD)

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; INOSITOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MENTAL DISEASE; MONOTHERAPY; PRESCRIPTION; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SMOKING; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; UNITED STATES;

EID: 77950385232     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005500304     Document Type: Review

References (43)

1. Sachs GS, Thase ME, Otto MW, et al. Rational, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry. 2003;53:1028-1042.
2. Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord. 2003;5(2):7-19.
3. Canadian Network for Mood and Anxiety Treatments (CANMAT). The treatment of bipolar disorder: review of the literature, guidelines, and options. Can J Psychiatry.1997;42(2):67S-100S.
4. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2001;158(2):325-326.
5. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912.
6. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55(9):391-393.
7. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722.
8. Thase ME. Treatment of refractory bipolar depression. Curr Psychiatry Rep. 2007;9(6):495-496.
9. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry. 2000;8(3):124-140.
10. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007;64(4):419-426.
11. Miklowitz DJ, Scott J. Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disord. 2009;11(2):110-122.
12. Nierenberg AA, Ostacher M, Calabrese J, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210-216.
13. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;2:79-88.
14. Chengappa KN, Levine J, Gershon S, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2000;2:47-55.
15. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
16. Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166(2):173-181.
17. Nierenberg AA. Lessons from STEP-BD for the treatment of bipolar depression. Depress Anxiety. 2009;26(2):106-109.
18. Perlis RH, Ostacher MJ, Patel J, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163:217-224.
19. Marangell LB, Dennehy EB, Miyahara S, et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord. 2009;114(1-3):58-67.
20. Perlis RH, Dennehy EB, Miklowitz DJ, et al. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord. 2009;11(4):391-400.
21. Demeter CA, Townsend LD, Wilson M, et al. Current research in child and adolescent bipolar disorder. Dialogues Clin Neurosci. 2008;10(2):215-228.
22. Bellivier F, Golmard JL, Schulze TG, et al. Age at onset in bipolar I affective disorder: further evidence for three subgroups. Am J Psychiatry. 2003;160:999-1001.
23. Carter TD, Mundo E, Parikh SV, et al. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res. 2003;37(4):297-303.
24. Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2008;165:370-377.
25. Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs. 2005;19(7):557-569.
26. Otto MW, Simon NM, Wisniewski SR, et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189:20-25.
27. Galanter CA, Beibenluft E. Frontiers between attention deficit hyperactivity disorder and bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2008;17(2):325-346.
28. Wingo AP, Ghaemi SN. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. J Clin Psychiatry. 2007;68(11):1776-1784.
29. Nierenberg AA, Miyahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005;57(11):1467-11173
30. Weiss RD, Ostacher MJ, Otto MW, et al. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry. 2005;66(6):730-735.
31. Fossey MD, Otto MW, Yates WR, et al. Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants. Am J Addict. 2006;15(2):138-143.
32. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106-123.
33. Waxmonsky JA, Thomas MR, Miklowitz DJ, et al. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen Hosp Psychiatry. 2005;27(5):321-328.
34. Pompili M, Rihmer Z, Innamorati M, et al. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother. 2009;9(1):109-136.
35. Allen MH, Chessick CA, Miklowitz DJ, et al. Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. Suicide Life Threat Behav. 2005;35(6):671-680.
36. Morris CD, Miklowitz DJ, Wisniewski SR, et al. Care satisfaction, hope, and life functioning among adults with bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program. Compr Psychiatry. 2005;46:98-104.
37. Marangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord. 2006;8:566-575.
38. Bauer M, Wisniewski SR, Marangell LB, et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? J Clin Psychiatry. 2005;67(1):48-55.
39. Goldberg J, Allen MH, Endick C, et al. Suicidal ideation and naturalistic pharmacotherapy in STEP patients with bipolar disorder. Psychiatr Serv. 2005;56:1534-1540.
40. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467-1473.
41. Parikh SV. Bipolar disorder: therapeutic choices. 5th ed. Ottawa (ON): Canadian Pharmacists Association; 2007.
42. Parikh SV, Kennedy SH. Integration of patient, provider, and systems treatment approaches in bipolar disorder. In: Power M, editor. Mood disorders: a handbook of science and practice. London (GB): John Wiley & Sons, Inc; 2004.
43. Nierenberg AA, Ostacher MJ, Borrelli DJ, et al. The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. J Clin Psychiatry. 2006;67(11):3-7.